Malathion vs Rivastigmine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Cholinesterase Inhibitor

Malathion

Brand: Ovide

First FDA approval: 2014-01-31

Cholinesterase Inhibitor

Rivastigmine

Brand: Exelon

First FDA approval: 2007-07-06

Lowest NADACAcquisition cost floor across all NDCs

$3.19Per unit

$0.150Per unit

Average NADACAcross all dosage forms and strengths

$3.19Up to $3.19

$2.73Up to $22.01

Generic manufacturersActive ANDA holders — FDA Orange Book

11 total ANDAs filed

1347 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$515631Full year

$145.3MFull year

Part D claims (CY24)Total fills, all strengths

3K2K beneficiaries

1.2M266K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$203Per claim, all NDCs

$126Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

15Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes1 manufacturers

Yes13 manufacturers